These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 37231847

  • 21. Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE.
    Miyata K, Miura M, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H.
    Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007191. PubMed ID: 33541111
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.
    Liu J, Ye B, Su D, Qin S, Zhao W, Pang Y.
    Clin Rheumatol; 2023 Jan; 42(1):167-177. PubMed ID: 36129563
    [Abstract] [Full Text] [Related]

  • 23. Non-coronary cardiac events, younger age, and IVIG unresponsiveness increase the risk for coronary aneurysms in Italian children with Kawasaki disease.
    Fabi M, Andreozzi L, Frabboni I, Dormi A, Corinaldesi E, Lami F, Cicero C, Tchana B, Francavilla R, Sprocati M, Bigucci B, Balsamo C, Valin PS, Di Fazzio G, Iughetti L, Valletta E, Marchetti F, Donti A, Lanari M.
    Clin Rheumatol; 2021 Apr; 40(4):1507-1514. PubMed ID: 32936425
    [Abstract] [Full Text] [Related]

  • 24. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, Mossberg M, Kucera F, Tulloh R, Standing JF, Swallow V, McCormack R, Herberg J, Levin M, Wan M, Klein N, Connon R, Walker AS, Brogan P.
    Trials; 2023 Jan 26; 24(1):60. PubMed ID: 36703139
    [Abstract] [Full Text] [Related]

  • 25. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
    Berdej-Szczot E, Małecka-Tendera E, Gawlik T, Firek-Pędras M, Szydłowski L, Gawlik A.
    Kardiol Pol; 2017 Jan 26; 75(3):261-266. PubMed ID: 27995598
    [Abstract] [Full Text] [Related]

  • 26. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
    Postgrad Med; 2018 May 26; 130(4):442-447. PubMed ID: 29745742
    [Abstract] [Full Text] [Related]

  • 27. A practical nomogram for predicting coronary thrombosis for Kawasaki disease patients with medium or large coronary artery aneurysm.
    Peng Y, Cheng Z, Yi Q.
    Clin Exp Med; 2023 Aug 26; 23(4):1317-1324. PubMed ID: 36151486
    [Abstract] [Full Text] [Related]

  • 28. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis.
    Friedman KG, Gauvreau K, Baker A, Son MB, Sundel R, Dionne A, Giorgio T, De Ferranti S, Newburger JW.
    Arch Dis Child; 2021 Mar 26; 106(3):247-252. PubMed ID: 32943389
    [Abstract] [Full Text] [Related]

  • 29. [Analysis of 2 diagnostic criteria of echocardiography for coronary artery aneurysm in Kawasaki disease].
    Liu WQ, Xia B, Fan W, Yu Z, Lin WL, Chen L, Wang C, Liu BN, Li J, Yang J.
    Zhonghua Er Ke Za Zhi; 2022 Jun 02; 60(6):588-593. PubMed ID: 35658368
    [Abstract] [Full Text] [Related]

  • 30. Blood routine risk factors for coronary artery aneurysm in infants younger than 8 months with Kawasaki disease.
    Haiyan G, Jianming L, Suqian T, Dong Q, Shuang L, Jin Z.
    BMC Pediatr; 2022 Jan 07; 22(1):29. PubMed ID: 34996405
    [Abstract] [Full Text] [Related]

  • 31. The factors affecting the disease course in Kawasaki disease.
    Arslanoglu Aydin E, Ertugrul I, Bilginer Y, Batu ED, Sonmez HE, Demir S, Arici ZS, Sag E, Alehan D, Ozen S.
    Rheumatol Int; 2019 Aug 07; 39(8):1343-1349. PubMed ID: 31139951
    [Abstract] [Full Text] [Related]

  • 32. Risk scores for Kawasaki disease, a management tool developed by the KAWA-RACE cohort.
    Grasa CD, Fernández-Cooke E, Domínguez-Rodríguez S, Aracil-Santos J, Barrios Tascon A, Sánchez-Manubens J, Mercader B, Antón J, Nuñez E, Villalobos E, Bustillo M, Camacho M, Oltra Benavent M, Giralt G, Bello Naranjo AM, Rocandio B, Calvo C, Spanish group for the study of Kawasaki Disease (KAWA-RACE).
    Clin Rheumatol; 2022 Dec 07; 41(12):3759-3768. PubMed ID: 35939163
    [Abstract] [Full Text] [Related]

  • 33. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
    Wu Y, Liu FF, Xu Y, Wang JJ, Samadli S, Wu YF, Liu HH, Chen WX, Luo HH, Zhang DD, Wei W, Hu P.
    Clin Exp Med; 2019 May 07; 19(2):173-181. PubMed ID: 30617865
    [Abstract] [Full Text] [Related]

  • 34. Clinical Presentation and Outcomes of Kawasaki Disease in Children from Latin America: A Multicenter Observational Study from the REKAMLATINA Network.
    Narayan HK, Lizcano A, Lam-Hine T, Ulloa-Gutierrez R, Bainto EV, Garrido-García LM, Estripeaut D, Del Aguila O, Gómez V, Faugier-Fuentes E, Miño-León G, Beltrán S, Cofré F, Chacon-Cruz E, Saltigeral-Simental P, Martínez-Medina L, Dueñas L, Luciani K, Rodríguez-Quiroz FJ, Camacho Moreno G, Viviani T, Alvarez-Olmos MI, Marques HHS, López-Medina E, Pirez MC, Tremoulet AH, Kawasaki Disease REKAMLATINA Network Study Group.
    J Pediatr; 2023 Dec 07; 263():113346. PubMed ID: 36775190
    [Abstract] [Full Text] [Related]

  • 35. The Harada score in the US population of children with Kawasaki disease.
    Tewelde H, Yoon J, Van Ittersum W, Worley S, Preminger T, Goldfarb J.
    Hosp Pediatr; 2014 Jul 07; 4(4):233-8. PubMed ID: 24986993
    [Abstract] [Full Text] [Related]

  • 36. Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease.
    Li W, Zhang L, Wang Z, He X, Lin H, Wang Y, Yuan J, Xie X, Zhang X, Qin Y, Huang P.
    Int J Clin Pract; 2022 Jul 07; 2022():2726686. PubMed ID: 35989868
    [Abstract] [Full Text] [Related]

  • 37. Intravenous immunoglobulin for the treatment of Kawasaki disease.
    Broderick C, Kobayashi S, Suto M, Ito S, Kobayashi T.
    Cochrane Database Syst Rev; 2023 Jan 25; 1(1):CD014884. PubMed ID: 36695415
    [Abstract] [Full Text] [Related]

  • 38. Epidemiology and Risk Factors for Giant Coronary Artery Aneurysms Identified After Acute Kawasaki Disease.
    Masuda H, Ae R, Koshimizu TA, Matsumura M, Kosami K, Hayashida K, Makino N, Matsubara Y, Sasahara T, Nakamura Y.
    Pediatr Cardiol; 2021 Apr 25; 42(4):969-977. PubMed ID: 33682062
    [Abstract] [Full Text] [Related]

  • 39. Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment.
    Downie ML, Manlhiot C, Collins TH, Chahal N, Yeung RSM, McCrindle BW.
    Int J Cardiol; 2017 Jun 01; 236():157-161. PubMed ID: 28089146
    [Abstract] [Full Text] [Related]

  • 40. Coronary artery aneurysm regression after Kawasaki disease and associated risk factors: a 3-year follow-up study in East China.
    Tang Y, Yan W, Sun L, Xu Q, Ding Y, Lv H.
    Clin Rheumatol; 2018 Jul 01; 37(7):1945-1951. PubMed ID: 29330741
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.